Biology Faculty Articles

Title

Atazanavir Sulfate. Fresh from the Pipeline

Document Type

Article

Publication Date

11-1-2003

Publication Title

Nature Reviews Drug Discovery

ISSN

1474-1776

Abstract

In June 2003, atazanavir sulphate (Reyataz; Bristol-Myers Squibb) — the first once-daily HIV-1 protease inhibitor — was approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents. Will its favorable dosing schedule and side-effect profile lead to success in this crowded and complex market?

This document is currently not available here.

Find in your library

Share

COinS